ClinicalTrials.gg
Not yet recruitingNCT07569575Updated Nov 3, 2026

Magnesium-Titanium Hybrid Intramedullary Nail System For Long Bone Fractures

An interventional study of Magnesium-Titanium Hybrid Intramedullary Nail System and Commercially Locked Metallic Intramedullary Nail in Tibial Fracture, Femoral Fracture and Humeral Fracture, sponsored by HuaMg Perfection Med Tech (Suzhou) Co., Ltd.. Not yet recruiting at 5 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by HuaMg Perfection Med Tech (Suzhou) Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 3, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a prospective, multicenter, randomized, controlled, non-inferiority clinical trial designed to evaluate the safety and effectiveness of the magnesium-titanium hybrid intramedullary nail system compared with the marketed metal locked intramedullary nail in the treatment of long bone fractures of the extremities.

Read the detailed description

Intramedullary nailing, a common surgical procedure to fix broken long bones, has a long history. As early as the 16th century, anthropologist Bernardino documented that local physicians in Mexico used wooden rods inserted into the bone marrow cavity to treat patients with unhealed long bone fractures. Modern metallic intramedullary nails were widely adopted after 1939, when Dr. KÜNTSCHER successfully treated femoral shaft fractures with V-shaped stainless steel nails. This technique was introduced to China in the early 1950s, and has since become the first-line treatment for fractures of the arm and leg bones, especially with the advancement of minimally invasive and biological fixation principles.

Traditional intramedullary nails rely on tight contact with the bone marrow cavity for stability. The later development of interlocking screws further improved stability, expanded clinical applications, and reduced complications. Compared with other fixation methods, intramedullary nails offer multiple advantages: they are inserted through small incisions to protect surrounding soft tissues, reduce infection risk, distribute stress evenly to avoid bone weakening, and allow early postoperative movement and weight-bearing, which speeds up recovery.

Currently, biodegradable magnesium and magnesium-based materials are a major global focus in orthopedic implant research. Magnesium is a naturally occurring metal that the body can absorb safely. It has excellent biocompatibility and mechanical properties very similar to human bone, making it an ideal revolutionary implant material. Growing evidence shows that magnesium ions released during the gradual degradation of magnesium implants can actively promote new bone growth and blood vessel formation, which is highly beneficial for fracture healing.

HuaMg Perfection Med Tech (Suzhou) Co., Ltd. has developed high-purity magnesium for orthopedic fixation implants. In preclinical animal studies conducted by qualified third-party institutions, a goat tibial fracture model experiment compared the company's magnesium-titanium hybrid intramedullary nail (experimental group) with conventional titanium alloy intramedullary nails (control group). The results demonstrated that the magnesium-titanium hybrid nail significantly promoted faster and more effective fracture healing than traditional titanium alloy nails.

Based on these promising preclinical findings, this prospective, multicenter, randomized controlled clinical trial is designed to evaluate the safety and effectiveness of the magnesium-titanium hybrid intramedullary nail system for treating long bone fractures of the extremities, compared with the commercially available locked metallic intramedullary nail.

02

Conditions studied

  • Tibial Fracture
  • Femoral Fracture
  • Humeral Fracture

Keywords

  • Magnesium-Titanium Hybrid Intramedullary Nail
  • Long Bone Fractures of the Extremities
  • Intramedullary Nailing
  • Biodegradable Magnesium Implant
03

In context

Tibial Fractures

136 studies on the registry are indexed under Tibial Fractures; 38 are open to participants now.

This study's planned enrollment of 160 is above the median of 66 across 92 interventional studies indexed under Tibial Fractures.

Browse Tibial Fractures studies →

Lead sponsor

This is the only study on the registry with HuaMg Perfection Med Tech (Suzhou) Co., Ltd. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years and ≤ 80 years (inclusive), with skeletal maturity, regardless of gender;
  2. Diagnosed with long bone fractures of the extremities (including femur, tibia, humerus) requiring surgical fixation with intramedullary nail;
  3. Good treatment compliance, willing and able to complete follow-up and observation as required;
  4. Voluntarily participate in this trial and sign the written form.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women, or individuals with family planning during the study period;
  2. Pathological fractures (e.g., bone tumor, bone , osteomalacia), or patients with too narrow or occluded medullary cavity;
  3. Patients complicated with osteomyelitis, osteofascial compartment syndrome, systemic infection or local infection at the surgical site;
  4. Patients with severe bone defects requiring artificial bone or autologous bone grafting;
  5. Patients with severe soft tissue or vascular injury, or previous surgical treatment at the fracture site, where intramedullary nailing may not provide stable fixation;
  6. Patients without sufficient soft tissue coverage at the proposed surgical site;
  7. Patients diagnosed with severe osteoporosis by the investigator based on medical history and X-ray films of the fracture site;
  8. Patients requiring simultaneous use of both intramedullary nail and screw-plate system at the planned surgical site;
  9. Patients with hypermagnesemia (serum magnesium > 1.25 mmol/L (3.0 mg/dL));
  10. Patients with uncontrolled diabetes mellitus ( HbA1c ≥ 8.0%);
  11. Patients with severe cardiovascular, hepatic, renal, pulmonary, hematological diseases or metabolic disorders who cannot tolerate surgery;
  12. Patients with previous or concurrent malignant tumors (excluding those cured and disease-free survival for more than 5 years, such as basal cell carcinoma of the skin, cervical carcinoma in situ, and papillary thyroid carcinoma);
  13. Patients who have received radiotherapy, chemotherapy, growth factors, , systemic , long-term (continuous use for more than 3 months) sedative-hypnotics, non-steroidal anti-inflammatory drugs, or bisphosphonates within 6 months prior to screening;
  14. Patients with constitutions allergic to the implanted materials or known allergies;
  15. Patients who have participated or are participating in any drug clinical trials within 3 months, or other medical device clinical trials within 30 days;
  16. Other conditions where the investigator determines the patient is unsuitable for inclusion (e.g., metabolic bone disease, poliomyelitis sequelae, etc.).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Magnesium-Titanium Hybrid Intramedullary Nail System

    Indicated for intramedullary fixation and fracture healing promotion in humeral, femoral, and tibial diaphyseal, proximal, and distal extremity fractures during orthopedic surgery.

    Device: Magnesium-Titanium Hybrid Intramedullary Nail System

  • Active comparator
    Commercially Locked Metallic Intramedullary Nail

    Indicated for internal fixation of long bone fractures of the extremities.

    Device: Commercially Locked Metallic Intramedullary Nail

Interventions

  • DeviceMagnesium-Titanium Hybrid Intramedullary Nail System

    The magnesium-titanium hybrid intramedullary nail system is inserted into the medullary canal through the proximal or distal end of the bone via standard intramedullary fixation surgical procedures, achieving fixation of the fracture site through intramedullary stabilization. This device provides load-sharing fixation for the fracture. The titanium alloy main body of the product delivers continuous, reliable mechanical support to ensure the overall stability of fracture fixation. The biodegradable magnesium components gradually degrade in vivo, releasing magnesium ions that participate in regulating the local bone repair microenvironment, thereby synergistically supporting the fracture healing process.

  • DeviceCommercially Locked Metallic Intramedullary Nail

    Commercially available metallic intramedullary nails including the humeral intramedullary nail (NMPA Registration No. 20233130578) and locked intramedullary nail (NMPA Registration No. 20163131478) manufactured by Shandong Weigao Orthopaedic Device Co., Ltd. are selected as the control devices based on the following reasons: 1) Shandong Weigao Orthopaedic Device Co., Ltd. is a leading orthopaedic enterprise in China, and its products are widely used in clinical practice with well-established efficacy and safety profiles; 2) The indications of the control devices fully cover those of the investigational device.

06

What researchers measure

Primary outcomes

  1. Effective rate of the product at 180 days postoperatively

    "Product effectiveness" is defined as the simultaneous fulfillment of the following criteria: (a) Fracture healing assessment criteria: no local tenderness or longitudinal percussion pain, no abnormal local movement; on radiographs of the fracture site, the fracture line is obscured or obliterated, or continuous callus or trabecular bone crossing the fracture line is visible. (b) No deformation, loosening, or breakage of the implanted product. Calculation formula: Product effectiveness rate at 180 days postoperatively = (Number of cases with effective product at 180 days postoperatively ÷ Total number of cases in the group) × 100%

    Time frame: 180±14 days postoperatively

Secondary outcomes

  1. Fracture healing status

    Fracture healing status will be documented at various follow-up time points after surgical reduction and internal fixation, and the fracture healing rate will be calculated. Fracture healing assessment criteria: No local tenderness or longitudinal percussion pain, and no abnormal local mobility; On radiographs of the fracture site, the fracture line is obscured or obliterated, or continuous callus or trabecular bone crossing the fracture line is visible. Calculation formula: Fracture healing rate = (Number of cases with fracture healing ÷ Total number of cases in the group) × 100%

    Time frame: 42±7 days, 90±7 days, and 180±14 days postoperatively

  2. Surgical duration

    The duration from the start of skin incision to the completion of wound closure and suture. Calculation method: The mean operative time will be calculated separately for the investigational group and the control group.

    Time frame: Intraoperative

  3. Intraoperative estimated blood loss

    The estimated intraoperative blood loss (mL) will be recorded, based on the official operative record.

    Time frame: Intraoperative

  4. Evaluation of Device Operability

    Device operability will be evaluated according to the following criteria, and the excellent-good rate will be calculated. Evaluation Criteria: Excellent: Complete configuration, simple operation, strong operability, and excellent compatibility of all components; Good: Complete configuration, acceptable operation, acceptable operability, and acceptable compatibility of all components; Fair: Average configuration, average operation, average operability, and average compatibility of all components; Poor: Incomplete configuration, cumbersome operation, poor operability, and poor compatibility of all components. Calculation Formula: Device Operability Excellent-Good Rate = (Number of cases rated Excellent or Good) ÷ (Total number of cases in the group) × 100%

    Time frame: Day of Surgery

  5. Occurrence of Adverse Events

    Definition: Includes the incidence rate (%) and number of events for (serious) adverse events, as well as the incidence rate (%) and number of events for device-related (serious) adverse events. Adverse events include, but are not limited to, deformation, breakage, and loosening of the intramedullary nail and locking components, as well as infection, compartment syndrome, nerve injury, non-union, delayed union, and other complications.

    Time frame: Through study completion, with an average follow-up duration of 180 days (range: 166-194 days postoperatively)

  6. Laboratory Examinations

    Routine blood tests (RBC, WBC, HGB, PLT), electrolyte tests (Ca²⁺, Mg²⁺), routine urine tests (RBC, PRO, WBC), and blood biochemistry tests (ALT, AST, TBIL, BUN/UREA, Cr) will be performed, and the laboratory findings of the experimental group and control group will be recorded.

    Time frame: Within 7 days after surgery, 42±7 days postoperatively (electrolytes only), 90±7 days postoperatively (electrolytes only), 180±14 days postoperatively (electrolytes only)

  7. Occurrence of Device Deficiencies

    Investigators will observe and record any device deficiencies that occur with the medical device under normal use during the clinical trial, including labeling errors, quality issues, malfunctions, etc. The incidence rate (%) and number of device deficiency events will be calculated.

    Time frame: Through study completion, with an average follow-up duration of 180 days (range: 166-194 days postoperatively)

07

Study locations

5 sites
  • Beijing Jishuitan Hospital, Capital Medical University
    Xicheng, Beijing Municipality, China
    • Maoqi Gong, PhD · Contactjst2603@126.com · +86 10 58517080
    • Xieyuan Jiang, PhD · Principal investigator
  • Henan Luoyang Orthopedic Hospital (Henan Orthopedic Hospital)
    Luoyang, He'Nan, China
    • Yunlong Liu, MD · Contactliuyunlongboa@163.com · +86 18037786581
    • Yanchun Shang, PhD · Principal investigator
  • Hebei Medical University Third Hospital
    Shijiazhuang, Hebei, China
  • Xi'an Honghui Hospital
    Xi'an, Shaanxi, China
    • Pengfei Wang, MD · Contactpengfei_wang@163.com · +86 13759994007
    • Kun Zhang, PhD · Principal investigator
  • Shanghai Jiao Tong University Affiliated Sixth People's Hospital
    Xuhui, Shanghai Municipality, China
    • Hongyi Zhu, PhD · Contact420308955@qq.com · +86 021 64369181
    • Changqing Zhang, PhD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2028, 16 months later.

Of 39 interventional studies with no phase under Tibial Fractures, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 80. This study's planned 16 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: start May 2026 → Nov 2026, primary completion Mar 2027 → Mar 2028 and completion Dec 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
May 6, 2026
StartEst.
Nov 1, 2026was May 2026
Primary completionEst.
Mar 31, 2028was Mar 2027
CompletionEst.
Dec 31, 2028was Dec 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 1, 2026→Nov 1, 2026
Nov 3, 2026
Primary completion
Mar 29, 2027→Mar 31, 2028
Nov 3, 2026
Study completion
Dec 31, 2027→Dec 31, 2028
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Start date May 1, 2026→Nov 1, 2026
    Primary completion Mar 29, 2027→Mar 31, 2028
    Study completion Dec 31, 2027→Dec 31, 2028
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07569575
Lead sponsor
HuaMg Perfection Med Tech (Suzhou) Co., Ltd.
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Mar 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Yuantao Zhang, PhD
Contact
ytzhang2008@163.com
+86 13421870043
Ling Qin, PhD
study director · Chinese University of Hong Kong

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion